Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(11):777; doi:10.1093/jnci/95.11.777-a
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 11, 777, June 4, 2003
© 2003 Oxford University Press

NEWS

In Brief

The first 10% of the full text of this article appears below.

High-Dose Chemotherapy Shows Promise Against Multiple Myeloma

High-dose chemotherapy combined with an autologous stem-cell transplant appears to be a more effective treatment for multiple myeloma than standard chemotherapy alone, according to a newly published randomized trial.

High-dose chemotherapy with stem-cell transplantation has increasingly been used as a first-line treatment for multiple myeloma despite the lack of data showing a survival benefit.

In a study in the May . . . [Full Text of this Article]

Fiber, Colorectal Cancer Connection Examined

FDA Approves Iressa for Advanced Lung Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?